Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors — Stella

Home/Diabetes/Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

View on ClinicalTrials.gov

Recruiting

Back to Diabetes trials

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

Hygea Medical Clinic, Montreal, Quebec

Key details

Phase

Early testing

Sponsor

McGill University

Enrollment target

~24 participants

Started

December 2024

Primary completion

January 2027

Age range

18 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.